These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1370539)

  • 1. Behavioral disinhibition and depression in amphetaminized rats: a comparison of risperidone, ocaperidone and haloperidol.
    Megens AA; Niemegeers CJ; Awouters FH
    J Pharmacol Exp Ther; 1992 Jan; 260(1):160-7. PubMed ID: 1370539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
    Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone.
    Leysen JE; Janssen PM; Gommeren W; Wynants J; Pauwels PJ; Janssen PA
    Mol Pharmacol; 1992 Mar; 41(3):494-508. PubMed ID: 1372084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
    Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF
    J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
    Janssen PA; Awouters FH
    Arzneimittelforschung; 1994 Mar; 44(3):269-77. PubMed ID: 7514873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional interaction between serotonin-S2 and dopamine-D2 neurotransmission as revealed by selective antagonism of hyper-reactivity to tryptamine and apomorphine.
    Awouters F; Niemegeers CJ; Megens AA; Janssen PA
    J Pharmacol Exp Ther; 1990 Sep; 254(3):945-51. PubMed ID: 1697623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity.
    Leysen JE; Janssen PM; Megens AA; Schotte A
    J Clin Psychiatry; 1994 May; 55 Suppl():5-12. PubMed ID: 7520908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro.
    Bowden CR; Voina SJ; Woestenborghs R; De Coster R; Heykants J
    J Pharmacol Exp Ther; 1992 Aug; 262(2):699-706. PubMed ID: 1380082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
    Gardell LR; Vanover KE; Pounds L; Johnson RW; Barido R; Anderson GT; Veinbergs I; Dyssegaard A; Brunmark P; Tabatabaei A; Davis RE; Brann MR; Hacksell U; Bonhaus DW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):862-70. PubMed ID: 17519387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical profile of risperidone, a new antipsychotic.
    Leysen JE; Gommeren W; Eens A; de Chaffoy de Courcelles D; Stoof JC; Janssen PA
    J Pharmacol Exp Ther; 1988 Nov; 247(2):661-70. PubMed ID: 2460616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological action of zotepine and other antipsychotics on central 5-hydroxytryptamine receptor subtypes.
    Czyrak A; Skuza G; Rogóz Z; Frankiewicz T; Maj J
    Arzneimittelforschung; 1994 Feb; 44(2):113-8. PubMed ID: 7511901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine, and 11 other antipsychotic agents.
    Millan MJ; Brocco M; Rivet JM; Audinot V; Newman-Tancredi A; Maiofiss L; Queriaux S; Despaux N; Peglion JL; Dekeyne A
    J Pharmacol Exp Ther; 2000 Jan; 292(1):54-66. PubMed ID: 10604931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
    Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
    J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
    Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography.
    Schotte A; Janssen PF; Megens AA; Leysen JE
    Brain Res; 1993 Dec; 631(2):191-202. PubMed ID: 7510574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of typical and atypical antipsychotic drugs on response decrement patterns in rats.
    Sanger DJ; Perrault G
    J Pharmacol Exp Ther; 1995 Feb; 272(2):708-13. PubMed ID: 7531764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
    Oka M; Noda Y; Ochi Y; Furukawa K; Une T; Kurumiya S; Hino K; Karasawa T
    J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risperidone reduction of amphetamine-induced self-injurious behavior in mice.
    Wagner GC; Avena N; Kita T; Nakashima T; Fisher H; Halladay AK
    Neuropharmacology; 2004 Apr; 46(5):700-8. PubMed ID: 14996547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent.
    Szewczak MR; Corbett R; Rush DK; Wilmot CA; Conway PG; Strupczewski JT; Cornfeldt M
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1404-13. PubMed ID: 7562515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survey on the pharmacodynamics of the new antipsychotic risperidone.
    Megens AA; Awouters FH; Schotte A; Meert TF; Dugovic C; Niemegeers CJ; Leysen JE
    Psychopharmacology (Berl); 1994 Feb; 114(1):9-23. PubMed ID: 7531353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.